The UK is a world leader in life science research. Yet many breakthroughs are lost in translation from preclinical animal models to humans. There is now a tremendous opportunity to bridge the translational gap with human relevant technologies.
It is time to focus on the human.

The Alliance for Human Relevant Science is an inclusive collaboration of like-minded companies, organisations and individuals. Working together, we will accelerate innovation and create positive change.

Latest

Thursday, August 7th, 2025

Lush Prize joins the Alliance for Human Relevant Science

The Alliance is pleased to welcome the Lush Prize as its newest organisational member.
Launched in 2012, the Lush Prize rewards initiatives across science and campaigning that work to end or replace animal testing with modern scientific methods. Since then it has awarded prize funding of almost £3 million to 140 successful projects worldwide across several categories; Science, Training, Public Awareness, Lobbying, Political Advocacy and Young Researchers, as well as further awards and commendations to recognise Political Achievement and Major Science Collaborations. Alongside funding awards, the Prize continues its work in communications, policy and outreach on the need to transition from animal-based research to approaches which are more human and environmentally relevant.
The aims of the Lush Prize align with the objectives of the Alliance to;
* Support better science for better health;
* To save lives – human and animal – through improved research, development safety and efficacy testing of medicines and other chemicals;
* To save money through more relevant research.

humanrelevantscience
lushprize


Friday, February 28th, 2025

Our new publication in Frontiers in Drug Discovery: How complex in vitro models are addressing the challenges of predicting drug-induced liver injury

We are very pleased to share our recently published paper in Frontiers in Drug Discovery on How complex in vitro models are addressing the challenges of predicting drug-induced liver injury.

Predicting which drugs might have the potential to cause drug-induced liver injury (DILI) is highly complex and the current methods, 2D cell-based models and animal tests, are not sensitive enough to prevent some costly failures in clinical trials or to avoid all patient safety concerns for DILI post-market. Animal-based methods are hampered by important species differences in metabolism and adaptive immunity compared to humans and the standard 2D in vitro approaches have limited metabolic functionality and complexity. The Alliance for Human Relevant Science hosted a workshop at the Royal Society, London entitled Drug-Induced Liver Injury (DILI): Can Human-Focused Testing Improve Clinical Translation? The conclusion was that complex in vitro models (CIVMs) provide a significant step forward in the safety testing paradigm. This perspective article, written by Dr. Katy Taylor and Alliance members representing collaboration across academia and industry, provides a ‘state of play’ on liver CIVMs with recommendations for how to encourage their greater uptake by the pharmaceutical industry.

Full citation: Taylor, K, Ram, R, Ewart, L, Goldring, C, Russomanno, G, Aithal, GP, Kostrezewski, T, Bauch, C, Wilkinson, JM, Modi, S, Kenna, JG, Bailey, J. Perspective: How complex in vitro models are addressing the challenges of predicting drug-induced liver injury.  Front. Drug Discov. 5 – 2025.

Read the full paper here


Wednesday, February 26th, 2025

Safer Medicines Trust publishes an evaluation of the UK’s Early Access to Medicines Scheme

Our paper on the UK’s Early Access to Medicines Scheme has just been published. We found that many drugs expedited as part of the scheme do not have an established safety profile, while several appear to have significant risks for patients. We argue that the Medicines and Healthcare products Regulatory Agency needs to insist on more robust evidence before fast tracking drugs, and that among other things, the safety of expedited drugs might be improved with greater preclinical use of human biology-based technologies.
Read the paper here: https://lnkd.in/dHSi4FkZ
Safer Medicines Trust

No alt text provided for this image

Thursday, January 23rd, 2025

One Month remaining to apply for Humane Research Trust Funding Grants

There’s only 1 month left to apply for our latest round of grant funding. If you’re a principal investigator seeking funding for a PhD or post-doctoral led project, make sure to get your application in before the deadline this February.

We’re looking for projects that advance human health and understanding of disease, as well as promote the replacement of animals in research.

Begin your application today: https://lnkd.in/efXtxKV6